Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

126.23 +0.04 (+0.03%)
Streaming Delayed Price Updated: 10:05 AM EDT, Apr 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
Healthcare Stocks Are Lagging With Big Earnings Weeks Ahead
Healthcare stocks disappointed again last week with the XLV down over 3% and up only 1.65 % YTD, in a continued downtrend since March 28. 
Via Talk Markets
Better Growth Play: Merck or The Vanguard Growth Index Fund?
Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund? 
Via The Motley Fool
Merck Paid $208 Million to Stop Its Drugs From Working. Here's Why That's Bullish.
Being able to stop a drug's unwanted effects could lead to a larger market share. 
Via The Motley Fool
1 New Green Flag for Moderna and Merck Stock
There's a new reason to believe that their joint projects are going well. 
Via The Motley Fool
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024
We’re using the Portfolio Grader to find the best biotech stocks to buy in today’s market. Each of these stocks get top grades. 
Via InvestorPlace
When you look at NYSE:MRK, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill
Understanding Merck &amp; Co's Position In Pharmaceuticals Industry Compared To Competitors
Via Benzinga
2 Dividend Stocks to Buy and Hold Forever
These dividends are about as safe as they come. 
Via The Motley Fool
Market Whales and Their Recent Bets on MRK Options
Via Benzinga
Declining COVID-19 Vaccine Sales Pinches Moderna, Pauses Kenya Vaccine Plant Plans
Moderna pauses plans for Kenya vaccine plant amid declining COVID-19 vaccine demand in Africa. Losses from unfulfilled orders prompt strategic shift. Efforts to finalize deal with Kenyan government... 
Via Benzinga
Exposures COVID-19
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease. 
Via InvestorPlace
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. Market dynamics are shifting towards adults, potentially doubling with the... 
Via Benzinga
The Pharmaceutical Industry Finds Itself At A Historical Crossroads
Bristol Myers Squibb (NYSE: BMY), Merck & Co Inc (NYSE: MRK), Pfizer Inc (NYSE: PFE) and Johnson & Johnson(NYSE: 
Via Benzinga
Expert Ratings For Merck & Co
Via Benzinga
Looking At Merck & Co's Recent Unusual Options Activity
Via Benzinga
Why Is Moderna Stock Trading Higher On Tuesday?
Moderna stock jumps post AACR 2024 presentation of mRNA-4157 + Keytruda data in advanced HPV-negative head and neck carcinoma. Positive responses in the Phase 1 trial, with a 27.3% objective response... 
Via Benzinga
Golden Years Gainers: 3 Stocks to Fund Your Dream Retirement
A popular and rewarding goal in investing is building a strong portfolio for retirement. These retirement stocks should help. 
Via InvestorPlace
Topics Retirement
Exposures Pension
Down 75%. Is Agenus Stock a Buy on the Dip?
Wall Street analysts who watch the cancer drug developer closely think it could rocket higher. 
Via The Motley Fool
The 3 Most Undervalued S&P 500 Stocks to Buy in April 2024
Our economy is on the up and up, and investing is a must. Let's review the most undervalued S&P 500 stocks to buy in April. 
Via InvestorPlace
Topics Economy Stocks
Exposures Economy US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Cancer-Focused eFFECTOR Therapeutics Shelves Development Of Lung Cancer Candidate After Disappointing Data
eFFECTOR Therapeutics unveils Phase 2 KICKSTART trial results for tomivosertib with Keytruda in NSCLC patients. Tomivosertib shows modest activity, but no clear path forward. Zotatifin emerges as a... 
Via Benzinga
Forget Shopify: This Stock Has Made Far More Millionaires
It's a reliable winner with plenty more room to run. 
Via The Motley Fool
Russell 2000 Index Best And Worst Performing Stocks Of 2024
The Russell 2000 index continued to underperform the Dow Jones and Nasdaq 100 indices in the first quarter of 2024. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Which Blue Chip Led The Dow Jones Industrials In Q1?
Disney and Caterpillar led gains among Dow Jones stocks in the first quarter. Boeing posted the largest decline. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
3 Strong Buy Healthcare Stocks to Add to Your Q2 Must-Watch List
In an aging world, strong buy healthcare stocks like UNH, ABT, and MRK shine with dividends, innovation, and market growth. 
Via InvestorPlace
Stock Market Rally Shows Breadth As Leaders Take A Breath: Weekly Review
The stock market rally showed breadth, with small caps leading the way to a 24-month high. Growth leaders like Nvidia took a break. 
Via Investor's Business Daily
Japan Index Falls While Asia And Europe Markets Rise, And Gold Exceeds $2,220 - Global Markets Today While US Slept
Via Benzinga
The Reserve Bank Of South Africa Kept The Rate At 8.25%
The Reserve Bank of South Africa unanimously decided to keep the key repo rate at 8.25%, marking the fifth consecutive meeting at 2009 levels, as expected. 
Via Talk Markets
Merck Stock Soars On FDA Approval for Winrevair: Technical Analysis And Market Outlook
Merck acquired sotatercept via its $11 billion acquisition of Acceleron Pharma, underscoring a commitment to advancing innovative therapies. 
Via Benzinga
Exposures Product Safety
The Most Important Catalyst For Merck's Stock In 2024 Could Be Sotatercept Launch, Analyst Says
Cantor Fitzgerald notes Merck's robust stock performance, up 15% YTD vs S&P 500's 10%.Potential peak sales projections ranging from $1 billion to $8 billion. Merck targets 40,000 potential patients. 
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.